Relapse Archives

Treatment that keeps half of people from relapsing for two years

Treatment that keeps half of people from relapsing for two years Published: 04 February 2022 More than half of people with multiple sclerosis (MS) who are treated with self-injected disease-modifying therapies (DMTs) had no evidence of disease activity after two years, a new study has found. Turkish researchers wanted to

Possible new treatment for MS on the horizon

Possible new treatment for MS on the horizonPublished: 30 June 2021 A new less expensive, more convenient treatment for multiple sclerosis (MS) could be on the horizon. Ublituximad, made by TG Therapeutics, has been shown to significantly reduce the annualised relapse rate in people with relapsing MS when compared with

Tysabri lessens disease activity and reduces relapses in paediatric-onset multiple sclerosis

Tysabri lessens disease activity and reduces relapses in paediatric-onset multiple sclerosis Published: 01 April 2021 Tysabri (natalizumab) significantly reduces disease activity and the number of relapses in people with paediatric-onset multiple sclerosis (POMS), new real-world study from Portugal has found. Tysabri is an off-label treatment, which means it hasn’t been

Switching from Tysabri increases risk of relapse

Switching from Tysabri increases risk of relapse Published: 18 June 2020 A new study has found the risk of a relapse for someone with relapsing remitting multiple sclerosis (RRMS) switching from Tysabri (natalizumab) to another injectable or oral after two or more years on the therapy is two to three

Treatment that keeps half of people from relapsing for two years

Possible new treatment for MS on the horizon

Tysabri lessens disease activity and reduces relapses in paediatric-onset multiple sclerosis

Switching from Tysabri increases risk of relapse

Get started

Ways to pay

Fundraise for us

© ms-uk.org all rights reserved